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The Liver is comprised of hepatocytes, the parenchymal cells, and non-parenchymal 
cells which includes stellate cells, portal fibroblasts, inflammatory cells and cholangiocytes. 
Cholangiocytes are the epithelial cells of the bile ducts, which carry bile from the liver to 
the duodenum. Bile ducts and specifically cholangiocytes are susceptible to disease; these 
diseases are classified as cholangiopathies. Primary Sclerosing Cholangitis (PSC) is a disease 
of both the extra- and intrahepatic bile ducts involving inflammation and obliterative 
fibrosis. The cause of PSC is, as yet unclear, but is thought to be autoimmune related. 
Inflammation of tissue surrounding the ducts leads to stricture and sclerosing of the duct 
and results in scar formation, thereby, leading to obstruction of bile flow. Chronic 
impairment of the duct accompanied by dysfunction of bile transport results in biliary 
fibrosis, progressive biliary cirrhosis and liver failure. PSC is increasing in prevalence, 
untreatable and, ultimately, requires transplantation. Given donor liver numbers have 
remained static over the last 30 years, modulating fibrosis is an attractive alternative to 
transplantation. Tissue fibrosis is a complex process involving the formation of an excess of 
fibrous tissue. Fibrosis is an important part of the regenerative process during injury. It 
requires balanced expression of fibrotic promotors (e.g. Transforming Growth Factor β 
(TGFβ) and Matrix Metalloproteinases (MMPs)) and inhibitors (e.g. Tissue Inhibitor of 
Metalloproteinases (TIMPs)) to maintain an environment conducive to tissue repair and 
continued organ function.  
The non-canonical Wnt signaling pathway has been, traditionally, shown to 
determine cellular polarity and cell migration during embryogenesis, however, its role in 
adult tissue homeostasis and regeneration is poorly understood. Examples of non-canonical 
Wnt pathway activation have been described during regeneration, for example, in skeletal 
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muscle, however the role of non-canonical Wnt signaling in the liver has not been 
elucidated. Briefly, the non-canonical Wnt pathway does not involve β-catenin, unlike the 
canonical pathway or calcium, as in the calcium mediated Wnt Pathway. Wnt ligand binds 
to a Frizzled (Fzd) receptor or a single pass receptor tyrosine-kinase (such as Ror2 or Ptk7) 
which can then interact with the co-receptor Van Gogh-like 2 (Vangl2). Activation of this 
receptor recruits Disheveled (Dsh) to the cell membrane. Downstream of Dsh the pathway 
can utilise a number of signaling cascades involving activation of DAAM1, Rho, Rac, ROCK 
and Jnk that ultimately leads to actin cytoskeletal modifications and/or transcription via AP-
1. Inhibition of these key downstream components has been shown to phenocopy 
knockout of the cell surface receptor elements demonstrating the specific nature of the 
pathway to its desired biological effect. Here we use a mouse model of PSC to show up-
regulation of the non-canonical Wnt pathway receptor-ligand complex and downstream 
activation of the Vangl2 mediated non-canonical Wnt pathway. Particularly, we show that 
Vangl2 and Wnt5a are up regulated at both the transcript and protein level and also 
demonstrate that these proteins are expressed in the regenerating ducts following PSC-
modelled injury. To functionally evaluate the role of Vangl2 in bile duct fibrosis we used 
Vangl2 mouse mutants, which contain either a C-terminus point mutation in Vangl2 or 
conditional loss of the transmembrane domain of Vangl2 to knockout Vangl2 function.  
Here we show that loss of Vangl2 results in a significant reduction of fibrosis 
following bile duct injury when compared to mice with intact Vangl2. The loss of Vangl2 
demonstrates that it has a central and hitherto unidentified role in liver fibrosis. In mice 
where Vangl2 is abrogated we have defined that Vangl2 regulates a number of gene 
families associated with inflammation and have, furthermore, identified candidate 
pathways through which Vangl2 can potentially act. These data together highlight the role 
of the non-canonical Wnt signaling pathway in the maintenance of the fibrotic niche. 
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Moreover, with the use of therapeutic Wnt inhibitors we are able to modulate bile duct 





The Liver is an essential organ, it plays a key role in metabolism but also fulfils other 
roles such as removal of red blood cells, detoxification, hormone production and the 
production of biochemicals used for digestion. The Liver is comprised of hepatocytes, which 
make up 70-85% of the liver’s mass, and other cells such as stellate cells, portal fibroblasts, 
inflammatory cells and cholangiocytes. Cholangiocytes line the vessel walls of the bile 
ducts, these ducts carry bile from the liver to the duodenum to help with the digestion of 
fats. As with most cells or structures, cholangiocytes are susceptible to disease; these 
diseases are known as cholangiopathies. Primary Sclerosing Cholangitis (PSC) is a disease of 
the bile ducts that involves inflammation and damaging fibrosis. The cause of PSC is, as yet 
unclear, but is thought to be autoimmune related, where the body’s own immune system 
attacks healthy cells. Inflammation of tissue surrounding the ducts leads to thickening of 
the vessel walls and narrowing of the duct itself and results in scar formation, thereby, 
leading to obstruction of bile flow. Over time, impairment of the duct accompanied by poor 
bile transport results in biliary fibrosis, progressive biliary cirrhosis and liver failure. PSC is 
increasing in prevalence, untreatable and, ultimately, requires transplantation. Given donor 
liver numbers have remained static over the last 30 years, investigating the causes of 
fibrosis, and targeting these therapeutically, is an attractive alternative to transplantation.  
Signaling pathways throughout the cells of the body dictate their response to a 
multitude of stimuli. One of these pathways is the Wnt pathway. The signaling protein, 
Wnt, binds to a receptor and in some cases co-receptor. Wnt doesn’t always bind to the 
same receptor nor does it always activate the same downstream signaling cascade within 
the cell when it binds to a receptor. Wnt signaling pathways can be grouped together based 
on some common features. One of these groups is the non-canonical Wnt signaling 
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pathway. The non-canonical Wnt signaling pathway has been shown to determine what 
defines the top and bottom of a cell as well as determining the direction of how cells move, 
giving cells direction and orientation. However, its role in adult tissue regeneration is poorly 
understood.  
Here we use a mouse which has PSC to show an activation of the non-canonical 
Wnt pathway and downstream activation of this pathway. Particularly, we have found that 
non-canonical Wnt ligands and receptors are increased specifically in the regenerating 
ducts. We have then removed this pathway genetically in mice by deleting a protein known 
as Van Gogh-like-2 (Vangl2) and can show that fibrosis is reduced. Showing for the first time 
that the role of the non-canonical Wnt pathway in liver is to activate the formation of 
fibrosis.  We are able to use very specific drugs that target the Wnt pathway and can show 
that treating with these drugs can modulate bile duct fibrogenesis and, for the first time, 
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Chapter 1: Introduction 
1.1 The Liver 
The liver acts as a vast chemical factory, synthesizing large complex molecules from 
low molecular weight substances brought to it in the blood particularly substances recently 
absorbed by the intestine and transported by a portal blood system. The liver also breaks 
down toxic substances brought to it by the hepatic artery, and synthesizes bile, which is 
transferred by a system of ducts (the biliary system) to the duodenum (Stanfield, 2012). 
All of the biochemical functions of the liver are carried out by the epithelial parenchymal 
cell of the liver, the hepatocyte, and are dependent on complex inter-relationships 
between: 
 The vasculature (hepatic artery and portal vein branches, sinusoids and central 
veins) 
 The hepatocytes 
 The bile drainage systems (the canaliculi and intrahepatic bile duct) 
 
1.2 Vasculature 
The liver receives blood from two vessels, the hepatic artery and the hepatic portal 
vein (Stevens & Lowe, 1996).  The hepatic artery perfuses the liver with oxygenated blood 
from the celiac axis branches of the aorta. On entering the liver, it divides into increasingly 
smaller branches. The hepatic portal vein carries blood from the digestive tract that is rich 
in amino acids, lipids, and carbohydrates absorbed from the bowel, and also blood from the 
spleen, which is rich in haemoglobin breakdown products. After entering the liver at the 
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porta hepatis, the portal vein divides into smaller distributing veins, which then branch 
further, eventually forming terminal portal venules. In the liver, the two input circulations 
(hepatic artery and hepatic portal vein) discharge their blood into a common system of 
small vascular channels, the sinusoids, which are in intimate contact with the hepatocytes. 
The hepatic artery branches supply oxygenated blood containing metabolites for 
reprocessing and toxins for detoxification by hepatocytes (Stanfield, 2012; Stevens & Lowe, 
1996). 
Recently it has come to light that the hepatobiliary vasculature plays a key role in 
liver regeneration, with the hepatic vascular niche, predominantly represented by liver 
sinusoidal endothelial cells, initiating regeneration and determining the correct spatial and 
metabolic zonation of regenerating hepatocytes. Initially, this was highlighted by the 
discovery that upon ablation of VEGF-A receptor-2 in the liver sinusoidal endothelial cells 
inhibited the initial regenerative burst of proliferation within the hepatocytic population 
and subsequently limited the regeneration of the hepatocellular mass. It was found that the 
endothelial cell transcription factor Id1 was key to the regenerative process driven by the 
liver sinusoidal endothelial cells. Knockout of Id1 in mice showed the same phenotype due 
to reduced expression of liver sinusoidal endothelial cells angiocrine factors, one of which is 
Wnt2 and the other HGF, indicating for the first time that the hepatic microvasculature has 




The main functional cell of the liver is the hepatocyte; they are the parenchymal 
tissue of the liver making up 70-85% of the liver's mass. These cells are involved in protein 
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synthesis and storage, transformation of carbohydrates, synthesis of cholesterol, bile salts 
and phospholipids, detoxification, modification, and excretion of exogenous and 
endogenous substances and the initiation of formation and secretion of bile (Stanfield, 
2012; Stevens & Lowe, 1996). 
Hepatocytes (liver cells), which are intimately associated with the network of blood 
vessels (sinusoids), are polarized polyhedral cells with three identifiable types of surface 
(Eroschenko, 2012; Stevens & Lowe, 1996). The hepatocyte surfaces are important because 
they are involved in the transfer of substances between the hepatocyte, blood vessels and 
bile canaliculi. The three types of surface are sinusoidal, canalicular, and intercellular. 
Sinusoidal surfaces are separated from the sinusoidal vessel by the space of Dissé. They 
account for approximately 70% of the total hepatocyte surface. They are covered by short 
microvilli, which protrude into the space of Dissé. Between the bases of the microvilli are 
coated pits which are involved in endocytosis (Eroschenko, 2012; Stevens & Lowe, 1996). 
The sinusoidal surface is the site where material is transferred between the sinusoids and 
hepatocytes and diffusion across this boundary is highly efficient. Canalicular surfaces are 
the surfaces across which bile drains from the hepatocytes into the canaliculi. They account 
for approximately 15% of the hepatocyte surface and are closely opposed except at the site 
of a canaliculus, which is a tube formed by the exact opposition of two shallow gutters on 
the surface of adjacent hepatocytes (Eroschenko, 2012; Stevens & Lowe, 1996). The 
intercellular surfaces are the surfaces between adjacent hepatocytes that are not in contact 
with sinusoids or canaliculi. They account for about 15% of the hepatocyte surface. These 
intercellular surfaces are comparatively simple, but specialized for cell attachment and cell-




1.4 Intrahepatic Biliary Tree 
Bile produced by hepatocytes passes into bile canaliculi. The bile canaliculi carry the 
bile back to the portal tracts, away from the parenchyma. As the canaliculi approach the 
bile ductules in the portal tracts, they open into short passages, the canals of Hering, lined 
by small cuboidal epithelial cells, cholangiocytes (Eroschenko, 2012; Stevens & Lowe, 1996). 
Cholangiocytes are the epithelial cells of the bile duct. They are cuboidal epithelium in the 
small interlobular bile ducts, but become columnar and mucus secreting in larger bile ducts 
approaching the porta hepatis and the extrahepatic ducts (Eroschenko, 2012). 
In the healthy liver, cholangiocytes contribute to bile secretion via net release of 
bicarbonate and water. Several hormones and locally acting mediators are known to 
contribute to cholangiocyte fluid/electrolyte secretion. Examples would be secretin, 
acetylcholine and ATP (Stanfield, 2012). Maintenance of bile flow from the liver into the 
bowel is necessary for both hepatic health, but also is required for digestion of lipid.  
 
1.5 Liver Fibrosis 
 Fibrosis in the liver is caused by the excessive deposition of extracellular matrix 
(ECM). It is based on the interactions of hepatic stellate cells, which generate matrix, and 
are the resident livers cell and conditional infiltrating cells, such as macrophages and 
neutrophils.  
The ECM is comprised of secreted molecules that forms a structural and 
biochemical support niche to surrounding cells. Localized cells, which aggregate within the 
matrix secrete ECM components. Components can be classified into proteoglycans and 
non-proteoglycan polysaccharides, proteins and others components such as fibronectin and 
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laminin. Glycosaminoglycans are carbohydrate polymers that bind to proteins to form the 
proteoglycans. Common forms are heparin sulfate, chondroitin sulfate and keratin sulfate. 
Hyaluronic acid is an example of a non-proteoglycan. Proteins within the ECM are of 
particular interest as they are the most abundant component of the ECM and consititue 
what we commonly see as the fibrotic response. Two principle fibrotic proteins are collagen 
and elastin. Collagen is the most prolific of these scar-forming proteins and gives structural 
support., There are fourteen types of collagen (Type I-XIV) which can be sub-divided into 5 
groups; fibrillar (Type I-III, V, XI), facit (Type IX, XII, XIV), short chain (Type VIII and X), 
basement membrane (Type IV) and other (Type VI, VII, XIII). These different collagens 
contribute to disease processes in diverse ways. Elastins provide elasticity, giving the tissue 
the ability to move in response to force and return to its original form and is another major 
component of scar formation, however has been shown to be highly resolvable. Although 
there are many cell types that generate ECM specific to their localization, fibroblasts are 
the most common cell type involved and arise from the differentiation of non-fibrogenic 
pre-cursor cells. 
In terms of tissue regeneration, the extracellular matrix prevents the immune 
system reacting to the injury and responding with inflammation and scar tissue. The ECM 
also facilitates the surrounding epithelial cells to repair the tissue and has an instructive 
role in regeneration, providing many of the necessary signals for regeneration, thereby 
preventing the deposition of scar tissue. Fibrosis is a homeostatic occurrence that can exist 
between normal expression of ECM and extreme examples that can end in cirrhosis. This 
homeostatic process is an essential part of tissue maintenance and regeneration but 
excessive formation of scarring will lead the inefficient recovery of the tissue architecture 
or the generation of non-functional tissue. The homeostatic nature of fibrosis (i.e. its ability 
to form and then regress) during injury, maintains the liver’s integrity and function. This 
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combined with the remarkable regenerative capacity of the liver epithelium enables the 
organ to recover to a healthy functional state from chronic damage. Of course, protracted, 
iterative injury results in irreversible damage with cirrhosis and is largely irreversible due to 
collagen cross-linking within the ECM. This is mediated by the oxidation of lysine residues in 
collagen and elastin that promotes their polymerization and achieving a form that the body 
cannot remove.  
  Following injury and disease hepatic stellate cells (HSCs) become activated 
by signals that promote transdifferentiation of the quiescent HSCs to a myofibroblastic 
phenotype (TGFβ, IL6). This activation is characterized by the expression of α-smooth 
muscle actin by fibroblasts and a parallel loss of retinoids and lipid droplets, a reduction in 
the expression of adipogenic/lipogenic factors, and de novo expression of receptors for 
pro-fibrogenic, pro-chemotactic, and mitogenic factors. These cells differentiate into a 
myofibroblast (MFB) phenotype and begin to express ECM components within the liver 
tissue. Since fibrosis is a homeostatic state, if the insult is temporary and the injury quickly 
resolved, then these changes are transient. However, a sustained insult with chronic 
inflammation would lead to persistent and long-term activity of HSCs and MFBs and would 
result in the chronic accumulation of ECM. This accumulation inhibits liver function by the 
disruption of normal liver architecture and the substation of liver parenchyma with scar 
tissue, resulting in reduced function in the tissue.  
 ECM homeostasis can be further perturbed in chronic liver disease by the 
disruption in activity of matrix metalloproteinases (MMPs) and their corresponding 
inhibitors (TIMPs). MMPs encompass a family of zinc- and calcium-dependent enzymes 
whose role is to degrade ECM proteins and thus maintain homeostasis. Activated HSCs and 




Cholangiopathies, account for 18% of all adult liver transplants and the vast 
majority of paediatric cases. Cholangiopathies are a group of chronic liver diseases in which 
the biliary epithelium becomes occluded or damaged leading to the formation of scar tissue 
surrounding the bile duct (Nakanuma, 2012) . 
Cholangiocytes are able to proliferate in response to endogenous or exogenous 
signals/stimuli and play a key role in inflammatory and reparative processes within the liver 
(Glaser & Gaudio, 2009; Greenbaum & Wells, 2011). Furthermore, cholangiocytes interact 
with the immune system and microorganisms and are involved in drug metabolism. To 
accomplish these multifaceted functions, cholangiocytes display morphologic and 
functional heterogeneity along the biliary tree. Cholangiocytes lining large bile ducts (300 – 
800µm) participate in hormone-regulated bile secretion, whereas cholangiocytes lining 
small bile ducts (15–300µm) possess proliferative capabilities and display considerable 
plasticity, being able to assume a “reactive phenotype” in disease conditions and 
potentially house the liver progenitor cell, the oval cell. Cholangiocytes represent the 
primary cell target of a diverse group of genetic and acquired biliary disorders collectively 
referred to as cholangiopathies. Many of the cholangiopathies are, at their early stages, site 
restricted along the biliary tree. For instance, primary biliary cholangitis (PBC), drug-induced 
cholangiopathies, and graft vs. host disease (GVHD) involving the liver affect primarily the 
small bile ducts. In contrast, primary sclerosing cholangitis (PSC) mainly involves the large 
intra- and extrahepatic bile ducts (Fava, 2010; Nakanuma, 2012). Thus, recognition of 
cholangiocyte heterogeneity along the biliary tree is necessary to understand better the 
cholangiopathies and, potentially, to devise novel, effective therapies. Because of their 
morbidity, mortality, need for liver transplantation, and overall cost to society, 
cholangiopathies are now recognized as an important group of liver diseases. Most 
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cholangiopathies display a progressive course leading to cirrhosis and liver failure. To date, 
the cause of most cholangiopathies remains obscure, although current thought seems to be 
settling on them being triggered by autoimmunity, thus treatment for these diseases 
remains under developed, with liver transplant offering the only curative option to treat 
these diseases. 
 
1.7 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC), a xenobiotic model of bile duct 
injury  
 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) acts by inducing increased 
porphyrin secretion and its deposition in the form of occluding plaques in bile ducts. This 
leads to inflammation surrounding the ducts and subsequently fibrosis. DDC is widely used 
to investigate Mallory body formation, as seen in alcoholic liver disease, as well as oval cell 
activation and proliferation. Oval cells are bipotential stem cells that reside within the 
canals of Hering. They can differentiate into either hepatocytes or cholangiocytes. A murine 
model of bile duct disease requires the supplementation of standard diet with DDC and 
shows a strong ductular reaction, which increases over time. In biliary cells the expression 
of vascular cell adhesion molecule (VCAM), osteopontin, TNF-α, Notch and Hedgehog are 
upregulated following the administration of DDC. Histopathologically, dietary 
administration of DDC leads to small duct sclerosis with infiltration of inflammatory 
mononuclear cells and activation of portal fibroblasts, causing biliary liver fibrosis. Murine 
liver challenge with DDC is a suitable model of primary sclerosing cholangitis in humans as 
the biliary inflammation, ductular and cellular response around the bile ducts seen in DDC 




1.8 Wnt Signaling Pathways 
Wnt signaling was first identified in 1982 under the name Int1 (R Nusse, van Ooyen, 
Cox, Fung, & Varmus). It was subsequently shown to be evolutionarily highly conserved 
across species and had was characterised as Wingless (Wg) in Drosophila (R. van 
Amerongen & Nusse, 2009). Since it was understood that Wg functioned as a segment 
polarity gene involved in body axis formation, it was thought that Int1 (Wnt) would also be 
involved in embryonic development. Wnt signaling is a classic evolutionarily conserved 
pathway, it is consistently demonstrated to play an influential role in organisms particularly 
in embryonic development, tissue homeostasis and disease, where cellular proliferation 
and differentiation is required.    
Wnt signaling pathways fall into three categories, the canonical Wnt/β-catenin 
dependent, the non-canonical pathway, this pathway is β-catenin independent and the 
Wnt/Ca2+pathway, which is also independent of β-catenin (Niehrs, 2012).  The β-catenin 
dependent pathway has been thoroughly characterised in key model species. Activation of 
the canonical pathway results in inhibition of β-catenin’s destruction complex and thus an 
accumulation of β-catenin in the cytoplasm and its translocation to the nucleus, where it 
acts as a coactivator of transcription factors belonging to the TCF/LEF family. The Wnt/ β-
catenin pathway regulates stem cell pluripotency and cell fate decisions during 
development. However, the same thoroughness and level of description cannot yet be said 
for the non-canonical pathways that remains grossly under-described and characterised 







Figure 1 A simple diagrammatic representation by Niehrs et al (2012) outlining 
the three commonly referred to forms of Wnt signaling pathways. The 
Canonical, or β-Catenin dependent, pathway (B), the Calcium dependent Wnt-
Ca2+ pathway (C) and the Non-Canonical, or what is often referred to as the 
PCP (Planar Cell Polarity) pathway (A).  It also highlights the breadth of 
receptors and co-receptors that have been described as responding to Wnt 
ligands. These are but a small number of the more well described. 
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1.9 The Non-Canonical Wnt Mediated Pathways 
The non-canonical Wnt-mediated pathways are identified as operating 
independently from β-catenin. Historically, this has always been considered to be the Wnt-
Ca pathway and the Planar Cell Polarity Pathway (PCP). Fittingly, for a poorly described 
sibling of the canonical pathway there are, it seems multiple Wnt mediated, yet β-catenin-
independent pathway descriptions: Wnt-RAP1 signaling pathway, Wnt-Ror2 signaling 
pathway, Wnt-PKA pathway, Wnt-GSK3MT pathway, Wnt-aPKC pathway, Wnt-RYK 
pathway, Wnt-mTOR pathway, and Wnt/calcium signaling pathway. However, the task of 
deciphering their presence and roles is increasingly challenging as they can all show a 
degree of overlap between pathways and utilize common receptors and activate similar 
downstream pathways by activating transcription factors and antagonizing other signaling 
pathways. 
 Frizzled (Fzd) is a G-protein coupled receptor best known as a receptor for the Wnt 
family of secreted proteins (Takeuchi et al., 2003).  Activation of the Fzd receptor can be 
achieved by Wnt alone however this is a rare occurrence and more commonly a co-receptor 
is employed to achieve activation. In the canonical signaling pathway, the receptor LRP 
functions as a co-receptor. In the non-canonical Wnt signaling pathway the possible 
combination of co-receptors is much more extensive and include receptor and receptor-like 
tyrosine kinase (Ryk), ROR1/2, NRH1 or PTK7 (Zallen, 2007). Wnt protein binds to the N-
terminal extra-cellular cysteine-rich domain of Fzd (Takeuchi et al., 2003) (McNeill & 
Woodgett, 2010). The activated receptor complex then recruits Disheveled (DVL) from the 
cytoplasm, which uses its PDZ and DEP domains to form a complex with Disheveled-
associated activator of morphogenesis 1 (DAAM1) (McNeill & Woodgett, 2010). This 
triggers the activation of the small GTPases RHOA and RAC1, which in turn activates RHO-
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associated kinase (ROCK) and JUN-N-terminal kinase (JNK) (McNeill & Woodgett, 2010; 
Zallen, 2007). This leads to actin polymerisation, microtubule stabilisation as well as JNK-c 
JUN/cFOS dependent transcription (Cui, Capecci, & Matthews, 2011a; Takeuchi et al., 
2003). 
Recently, the distinction of the Wnt signaling pathways as separate and 
independent has come under debate with some evidence being published proposing 
interaction across pathways. This was highlighted with Wnt5a being shown to both activate 
Wnt/β-catenin via the canonical pathway but also that it’s activation of the non-canonical 
PCP pathway represses the canonical signalling pathway (Kawano & Kypta, 2003; V. 
Amerongen, Fuerer, Mizutani, & Nusse, 2012). 
 
1.10 Vangl2 
Mammalian Vangl2 is a highly conserved transmembrane protein commonly 
associated with the Planar Cell Polarity Pathway, a non-Canonical Wnt mediated pathway 
(Niehrs, 2012). It evolved from a single ancestral protein identified in Drosophila as 
Strabismus (Katoh, 2002). Vangl2 is involved in early morphogenesis, patterning of both 
axial midline structures and the development of the neural plate. Vangl2’s involvement in 
the PCP pathway was observed in the orientation of stereociliary bundles in the cochlea 
(Mlodzik, 2010), where loss of Vangl2 results in disorientation of stereocillia hairs. Vangls 
are known to act as a co-receptors with Fzd to receive Wnt ligand ( Gray, Roszko, & Solnica-
Krezel, 2011; Hatakeyama, Wald, Printsev, Ho, & Carraway, 2014). Of particular interest to 
the field at the moment, and the focus of current research in a number of groups, is the 
evidence supporting the role of ROR2 and/or PTK7 in forming a Wnt-induced non-canonical 
signaling complex with Vangl2 which results in the phosphorylation of Vangl2 (Gao et al., 
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2011; Martinez et al., 2015; Mouri et al., 2014). This interaction has been found to be Wnt 
dose-dependent. Furthermore, a similar relationship has been found to exist between Ryk 
and Vangl2 (Macheda et al., 2012). These interactions demonstrate a pathway whose 
description is still in its infancy and yet points to a series of complex interactions 
underpinning a variety of developmental, regenerative and physiological processes. 
There are two mouse homologs of Drosophila Stbm/Vang gene, Vang-like 1 
(Vangl1) and Vang-like 2 (Vangl2)(Katoh, 2002). The Vangl genes encode a four-
transmembrane domain protein with a C-terminal PDZ domain. Vangl2 is mutated in the 
Looptail (Lpt) mouse, a missense mutation on Chromosome 1 confers a point mutation and 
a non-synonymous amino acid change at the C-terminal cytoplasmic domain of Vangl2 that 
originated spontaneously and leads to destabilisation of the resulting protein (Yin, Copley, 
Goodrich, & Deans, 2012). Mice exhibiting heterozygosity for Vangl2 demonstrate a 
number of non-lethal phenotypes the most striking of which is a looped or kinked tail hence 
the commonly used term to describe them, Looptail. The Lpt mutation causes a failure in 
neural tube closure (craniorachischisis) in homozygous mutant animals, implicating a defect 
in the developmental role of the PCP pathway (Doudney & Stanier, 2005; Torban, Wang, 
Groulx, & Gros, 2004). Extensive work has been done on the role of the PCP pathway and in 
particular Vangl2 during cochlear development using the Lpt mouse model. The Lpt mice 
display pronounced polarization defects in the orientation of stereociliary bundles in the 
inner and outer hair cells of the mouse cochlea; this provided one of the first pieces of 
evidence supporting the existence of a conserved PCP pathway in the mammals 
(Montcouquiol et al., 2006; Zallen, 2007). The characterization of Lpt mice in the PCP 
regulation of the cochlea is highly significant and establishes the Lpt mice as a classic mouse 
model for PCP study. The Lpt mice have been used extensively for subsequent PCP studies 
to test genetic interactions in PCP signaling and to validate novel PCP genes. 
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Chapter 2: Aims, Hypothesis and Rationale 
Aim 1: Isolate and enrich for bile ducts from whole liver tissue. 
I predict that isolating bile ducts form whole liver will improve analysis of a relatively small 
population of cells. 
Bile ducts comprise a relatively small population of the whole liver. To ensure accurate 
analysis of the cells that comprise this structure it would be important to attempt to isolate 
or enrich for them to avoid the parenchymal cells masking or contaminating the output 
data. This holds particularly true if the marker or signal of interest is lowly expressed or if 
any hypothetical change occurring is small in the context of the whole organ but significant 
in the bounds of the ductual structure. 
 
Characterise Vangl2 and components of the non-canonical Wnt pathway in the liver 
during injury. 
I predict that the non-canonical Wnt pathway is activated during bile duct injury. 
The non-canonical Wnt mediated pathway and Vangl2 are, relatively, poorly described in 
the literature. There is some sparse evidence that it may play a role in the liver during 
injury. To investigate it is important to analyze the tissue under normal conditions and 






Aim 3: Investigate the response to modulation of Vangl2 in the liver during injury with the 
Looptail mouse. 
I predict that by using the Looptail mouse to modulate Vangl2’s activity we will gain insight 
into the role the non-canonical Wnt pathway plays during injury. 
By modulating Vangl2 we can observe the influence it has during injury on the downstream 




Chapter 3 – Materials and Methods 
 
3.1 Animal lines used in this study. 
All animals used in this study were housed in 12h light/dark cycles. When mice 
were not on an injury protocol they were maintained on RM1 animal food and normal 
drinking water. Male mice, aged 8 weeks, were used to model bile duct injury and 
regeneration. CD1 mice were used for all studies involved in defining changes during the 
experimental time-course and were bred in-house. Looptail (Lpt) mice, which contain a 
Vangl2 S464N mutation were imported from MRC Harwell, Oxford. These mice were 
supplied on a C3H background and were maintained at heterozygous crosses with C3H 
companion mice. All mice were fed 0.1% 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) 
food, made up in RM1 base feed for up to 14 days. Animals were maintained in accordance 
to UK Home Office regulations.  
 
3.2 Dissection and Fixation of Tissue. 
Adult mice were sacrificed by CO2 and cervical dislocation or exsanguination at the 
defined experimental endpoint. The liver was flushed through with PBS by rapid infusion 
through the inferior vena cava and out through the portal vein before tissues are dissected 
out from the animal. Tissue was fixed in 4% PFA for 24 hours then transferred to 75% 
Ethanol for 24 hours. Tissue was then processed for paraffin wax embedding using a Tissue-
Tek VIP unit. 
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Tissue sections were cut on a Leica RM2235 Manual Microtome at 3μm thickness, 
floated in a water bath and mounted on ThermoFisher Superfrost slides before being 
heated at 65°C for at least 20mins. 
For tissues which are to be used for RNA extraction, tissue was snap frozen using 2-
methylbutane super-chilled with dry ice. This tissue was stored at -80°C for future use. 
 
3.3 Picro-Sirius Red staining of total fibrillar collagen. 
3μm sections on glass slides were dewaxed through 3 consecutive washes of Xylene 
for 5minutes each. Following this the sections were rehydrated through decreasing 
concentrations of alcohol (100%, 90%, 75%, 50%) for 5 minutes each before finally being 
washed in water. The nuclei were staining using Mayer’s Haematoxylin for 10 minutes then 
washed in warm running water for 5 minutes. The sections were placed in picro-sirius red 
solution for 6 minutes. Upon reaching equilibrium staining the sections were rinsed in two 
changes of acidified water. The sections were dehydrated in three changes of 100% alcohol 
and cleared in 3 changes of Xylene for 5 minutes each. The sections were mounted with 
glass cover slips using DPX. 
 
Picro-Sirius Red Solution 
Sirius Red F3B   0.5g 
Saturated aqueous picric acid 500ml 
Acidified Water 





3.4 Immunohistochemistry Protocol 
3μm sections from mouse liver fixed in 4% PFA. Sections were dewaxed in Xylene 
for 3 x 5 minutes before being rehydrated through alcohol (100%, 90%, 75%, 50%) for 5 
minutes each before finally being washed in water. If necessary antigen retrieval and 
proteinase K digestion was carried out. Sections were washed in PBS for 5 minutes. Before 
being incubated in 3% hydrogen peroxide for 20 minutes at room temperature. The 
sections were mounted in a Sequenza staining rack. Sections were incubated with 120μl 
avidin blocker for 15 minutes at room temperature and then washed with 3 rinses of PBS 
for 5 minutes each. The sections were then incubated with 120μl biotin blocker for 15 
minutes at room temperature. The sections were then blocked for non-specific protein with 
a protein blocker for at least 30 minutes. 120μl of diluted primary antibody in antibody 
diluent was added to each slide and incubated at 4 ºC overnight. The sections were then 
rinsed in 3 changes of PBS for 5 minutes each. 120μl of diluted secondary antibody in 
antibody diluent was added to each slide and incubated for 1 hour at room temperature. 
The sections were, once again, rinsed in 3 changes of PBS for 5 minutes each. 3 drops of 
Vector RTU ABC reagent were added to each slide and incubated for 30 minutes att room 
temperature. Sections were rinsed 3 times in PBS for 5 minutes. 200μl of DAB reagent was 
added to each slide and incubated for up to 10 minutes depending on the intensity of 
staining required. The slides were rinsed with water and transferred to a rack and were 
counter-stained with Harris’s Haematoxylin for up to 30 seconds before being rinsed with 
running water and “blued” in Scott’s Tap Water. Finally, the sections were dehydrated 




3.4.1 Antigen Retrieval 
0.01M Citrate Buffer pH 6.0. 5 mins in microwave on high 
Tris-EDTA Buffer (10mM Tris Base, 1mM EDTA Solution, 0.05% Tween 20, pH 9.0) Pre-
heated for 5 mins in microwave then 2x5mins on high 
 
3.4.2 Proteinase K digestion 
6.25mg in 50 ml PBS @ 37ºC for 5 mins. Stock proteinase K = 25mg/ml 
 
3.4.3 Primary Antibodies 
Antigen Species Clone Catalogue # Company Dilutions Ag Retrieval 
aSMA Mouse 1A4 A2547 Sigma 1/2000 15m NaCt  
Collagen-1 Goat 
 
1310-01 SouthernBiotech 1/200 15m NaCt 
Desmin Rabbit 
 
ab8592 Abcam 1/100 15m NaCt  
PTK7 Rabbit 
 
17799-1-AP Proteintech 1/100 15m TE 
Vangl2 Rabbit 
 
HPA027043 Sigma 1/100 10m TE 
Wnt5a Rabbit 
 
LS-B4565 LS Bio 1/100 20m NaCt 
 
3.4.4 Secondary Antibodies 
Rabbit anti-Goat IgG (H+L) Secondary Antibody, Biotinylated Vector, 1/500 
Goat anti-Rabbit IgG (H+L) Secondary Antibody, Biotinylated Vector, 1/500 
Rabbit anti-Mouse IgG(H+L) Secondary Antibody, Life Technologies, 1/200 
Goat anti-Rabbit IgG (H+L) Secondary Antibody, HRP conjugate, Vector 1/500.  
For fluorescence, following secondary incubation sections were incubated with tyramide-
555 as per the manufacturer’s instructions. They were then heat treated with TE for 10m 
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and second primary antibodies were incubated with tissue followed by a second round of 
HRP secondary. This was then incubated with tyramide-488. 
 
3.5 mRNA isolation 
Snap frozen tissue was cut from the main block with a scalpel on dry ice. Tissue was 
homogenised using a Qiagen TissueRupter in 0.5ml Trizol LS (Amersham) for 5 minutes. The 
homogenate was briefly spun and mixed with one-fifth the volume of chloroform and 
vortexted for 30s. Chloroform and Trizol LS separate, and RNA is isolated from the aqueous 
phase. Trizol/Chloroform mixtures were spin at 12,000G for 15m at 4oC following which the 
aqueous phase is collected to a separate tube. The aqueous phase is mixed, 1:1 with 
isopropanol (Propan-2-ol) to precipitate RNA. This precipitated RNA is then applied to a 
Qiagen Micro kit tube and the protocol followed. Briefly, we washed the membrane with a 
wash of RW1 buffer followed by two washes of RPE. Membranes were spun to dry and then 
rehydrated with between 30 and 50μl RNAse/DNAse free dH2O. 
 
3.6 Reverse Transcription 
A Nanodrop was used to quantify the concentration of RNA in the sample. 1μg of 
RNA was made up to 12μl using dH2O. 2μl of Qiagen gDNAse is added and the solution 
vortexed to mix. The resulting mixture is incubated at 42oC for 5 minutes and then placed 
on ice for 2 minutes. 5μl of premixed random primers and mastermix was added. 1μl of 
reverse transcriptase was also added. Using a thermocycler the reaction was incubated at 
42oC for 30 minutes followed by 95oC for 3 minutes, to inactivate any remaining enzyme. 
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The cDNA samples can then be stored on ice for immediate use or frozen at -20oC for use at 




3.7 Quantitative PCR 
All Primer sets were provided by Qiagen and detailed in the table below: 
Gene Species Company Product Cat. # 
ABCB1 Mouse Qiagen QuantiTect Mm_Abcb1b_1_SG QuantiTect Primer Assay QT00140945 
Albumin Mouse Qiagen QuantiTect Mm_Alb_1_SG QuantiTect Primer Assay QT00115570 
Dvl1 Mouse Qiagen QuantiTect Mm_Dvl1_1_SG QuantiTect Primer Assay QT00106393 
Dvl2 Mouse Qiagen QuantiTect Mm_Dvl2_1_SG QuantiTect Primer Assay QT00112154 
Dvl3 Mouse Qiagen QuantiTect Mm_Dvl3_1_SG QuantiTect Primer Assay QT01079092 
Fzd1 Mouse Qiagen QuantiTect Mm_Fzd1_1_SG QuantiTect Primer Assay QT00290542 
Fzd2 Mouse Qiagen QuantiTect Mm_Fzd2_1_SG QuantiTect Primer Assay QT00261485 
Fzd3 Mouse Qiagen QuantiTect Mm_Fzd3_1_SG QuantiTect Primer Assay QT00147917 
Fzd4 Mouse Qiagen QuantiTect Mm_Fzd4_1_SG QuantiTect Primer Assay QT00260526 
Fzd6 Mouse Qiagen QuantiTect Mm_Fzd6_1_SG QuantiTect Primer Assay QT00109998 
Fzd7 Mouse Qiagen QuantiTect Mm_Fzd7_1_SG QuantiTect Primer Assay QT00307797 
Fzd8 Mouse Qiagen QuantiTect Mm_Fzd8_2_SG QuantiTect Primer Assay QT02328151 
Hnf1b Mouse Qiagen QuantiTect Mm_Hnf1b_1_SG QuantiTect Primer Assay QT00103320 
Hnf4a Mouse Qiagen QuantiTect Mm_Hnf4a_1_SG QuantiTect Primer Assay QT00144739 
Krt19 Mouse Qiagen QuantiTect Mm_Krt19_1_SG QuantiTect Primer Assay QT00156667 
Ptk7 Mouse Qiagen QuantiTect Mm_Ptk7_1_SG QuantiTect Primer Assay QT00144032 
Ror2 Mouse Qiagen QuantiTect Mm_Ror2_1_SG QuantiTect Primer Assay QT00172872 
Ryk Mouse Qiagen QuantiTect Mm_Ryk_1_SG QuantiTect Primer Assay QT00171724 
Sox9 Mouse Qiagen QuantiTect Mm_Sox9_1_SG QuantiTect Primer Assay QT00163765 
Vangl1 Mouse Qiagen QuantiTect Mm_Vangl1_1_SG QuantiTect Primer Assay QT00494235 
Vangl1 Human Qiagen QuantiTect Hs_VANGL1_1_SG QuantiTect Primer Assay QT00072548 
Vangl2 Mouse Qiagen QuantiTect Mm_Vangl2_1_SG QuantiTect Primer Assay QT00128422 
Vangl2 human Qiagen QuantiTect Hs_Vangl2_1_SG QuantiTect Primer Assay QT00512050 
Wnt4 Mouse Qiagen QuantiTect Mm_Wnt4_1_SG QuantiTect Primer Assay QT00104622 
Wnt5a Mouse Qiagen QuantiTect Mm_Wnt5a_1_SG QuantiTect Primer Assay QT00164500 
Wnt11 Mouse Qiagen QuantiTect Mm_Wnt11_1_SG QuantiTect Primer Assay QT00103663 
 
The reaction was made up as below (per reaction): 
5ul (50ng) of cDNA 
1.25ul Quantitect Primer Assay 




qPCR was run in triplicate in a 384-well format using a Roche lightcycler 480-II, for 
40 cycles. The cycling conditions were as follows: 
 Cycles Analysis Target Hold Ramp 
Pre-Incubation 1 None 95°C 5mins 4.8°C/s 


















Cooling 1 None 40°C 5mins  
 
All data was analysed using the 2ΔΔCt analysis method and normalised to uninjured controls 
or wild-type controls.  
 
3.8 RNAScope In Situ Hybridisation: 
RNAScope insitu hybridization was performed by Aquila Histoplex. The Boulter Lab 





3.9 Bile Duct Isolation and Organoid Culture 
Freshly flushed and dissected liver was cut into small pieces and immersed in 
dissociation media (12.5mg collagenase type XI (Sigma C9407), 12.5mg dispase (gibco 
17105-041) in 100ml DMEM 1% FBS) and incubated at 37°C in a water bath. The tissue 
fragments were agitated every 30mins using a 10ml automated pipette. The dissociation 
media was refreshed every hour for the first 2hours. After this time the supernatant was 
checked for ducts being present. When no ducts are present the supernatant can be 
pipetted off and disposed. When the ductual structures start to appear transfer the tissue 
suspension through an inverted 70µm cell strainer, re-invert the strainer into a 50ml tube 
and flush with media. This sample is now enriched for ductal structures and can be snap 
frozen and stored or used immediately as required.  
For organoid culture, transfer the supernatant to a 10cm dish and examine under a 
microscope at low magnification. Any ducts present can be transferred by hand using a 
pipette to a 15ml tube containing DMEM Glutamax with 5% FCS and 5% P/S. Centrifuge the 
collected ducts at 300g for 5mins and remove the supernatant. The pellet is then re-
suspended in 10ml of media without growth factors (Advanced DMEM/F12 with Glutamax, 
Hepes, P/S). Centrifuge the washed ducts again at 300g 2-3mins and remove the 
supernatant and put the collected pellet on ice. Add 20µl/well of Matrigel to the pellet and 
pipette gently to disrupt the pellet and re-suspend in Matrigel. Pipette 20µl into each well 
of a pre-warmed plate, the tip should be held off the base of the well so as to form a dome 
of matrigel containing suspended ducts, and transfer to an incubator for 10mins. Once the 
matrigel has solidified add 300-500µl of growth factor expansion media (Advanced 
DMEM/F12 with Glutamax, Hepes, P/S, mEGF, R-Spondin, Gastrin, Wnt3a, FGF10, HGF, n-
Actelycysteine, B27, A83-01 (TGFβ inhibitor), CHIR99021 (GSK Inihibitor), ROCK Inhibitor, 
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Forskolin) and return to the incubator. Organoids were fed every 2-3 days. The organoids 
were passaged using a mechanical dissociation method. The media was aspirated from 
each well and replaced with 300-500µl of chilled Versene. The Organoids were removed by 
pipette and agitated in the Versene. The re-suspended organoids were centrifuged at 300g 
for 5mins and the Versene removed. The pellet was re-suspended in chilled PBS and 
centrifuged at 300g for 5mins. Depending on the number of wells being passaged and 
volume of Matrigel removed it may be necessary to wash more than once to remove the 
Matrigel from the pellet. The Pellet can then be re-suspended as before in fresh Matrigel 




Chapter 4 – Isolation and culture of adult bile ducts to model 
the function of Vangl2 
4.1 Overview of Enrichment and Isolation of Bile Ducts 
The presence of Vangl2 and its signaling pathway members has not been examined 
in adult tissues before and there is little information Vangl2 expression in the liver. 
However, a single paper investigating the pathway in zebrafish indicated that Vangl2 and 
Vangl1 are important for duct generation. Therefore, to determine whether Vangl2 is 
expressed specifically in the bile ducts I sought to develop a method of enriching for bile 
ducts. Moreover, I wanted to be able to functionally use these ducts for over-expression 
and knockdown of Vangl2. To do this I needed to establish a bile duct organoid culture 
method in the lab, which had not been done before.  
Up to 85% of the mass of the liver is comprised of hepatocytes and non-bile duct 
cell types, it was therefore key to be able to enrich our samples for cholangiocytes and bile 
ducts prior to trying to establish bile duct organoid lines. Previous studies have shown that 
enrichment for cholangiocytes using cell surface markers, such as EpCAM, CD133 and CD24 
can isolate single cells and that these can form organoids in vitro. However, there are 
limitations to these methods; they are incredibly time-consuming, these markers do not 
necessarily represent the cellular diversity seen within the bile duct, and likely select for a 
primitive population of cells and the number of bile ducts organoids generated is relatively 
low.  
To this end, I developed a bile duct extraction protocol based on the original 
methodology by Huch et al. Briefly, whole livers were flushed with PBS through the Inferior 
Vena Cava (IVC) and dissected into PBS. During the development of this protocol I found 
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that roughly slicing them into smaller pieces was more effective than finely slicing them as 
the fragments of bile ducts that were ultimately generated were more substantial, due to 
this the ducts could be identified and isolated more easily and therefore many more 
organoids could be generated per section of duct. To remove hepatocytes from these tissue 
fragments I incubated the tissue in DMEM/Hams-F12 with dispase and collagenase. By 
pipetting these tissue slices up and down could disaggregate the hepatocytes from the 
biliary tree, but largely maintain the structure and cellularity of the bile ducts. The 
hepatocytes were dissociated from the ducts over several hours and changes of media with 
repeat pipetting. By the end of this process, almost all of the hepatocytes have been lost to 
the media changes and what remains are bile ducts and single cells. To further enrich for 
the ductal population the digested livers were passed through a 70μm filter to remove 





Figure 4.1 A diagrammatical representation of bile duct extraction. Whole liver is roughly 
sliced and through repeated incubations in disassociation media the parenchymal cells are 
removed to leave the bile ducts intact. The extracted ducts can be used immediately or 
stored for use at a later date. For organoid generation the ducts are embedded in Matrigel 
and supplied with a growth factor enhanced culture media. Within 24hours the extracted 
ducts “cap off” their open ends, by 48 hours small cystic-like buds can be seen on the 
ducts. After 3-5 days spherical organoids of a variety of sizes will be present while the 
original ductual structure will no longer be visible. 
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4.2 Validation of the Bile Duct Enrichment Protocol 
 My method of bile duct enrichment produces a visible population of ducts from 
whole liver by the sequential removal of parenchymal cells. I wanted to confirm this to 
determine that I have indeed enriched for bile ducts and also to try and determine what the 
level of contamination is, by hepatocytes, in the bile duct fraction following enrichment. To 
do this I took a portion of liver and isolated mRNA from this. The remaining liver was then 
subjected to my bile duct isolation protocol and bile ducts were enriched. These bile ducts 
were washed with PBS and then pelleted, lysed and mRNA was extracted. Using RT-qPCR I 
investigated a number of hepatocyte and bile duct markers to determine whether certain 
components of markers are enriched in particular fractions.  
Cytokeratin 19 (KRT19) is a key marker of bile ducts. The Keratin gene family are 
important for intracellular stability in epithelial tissue with different members of the family 
displaying organ or tissue specific expression patterns. Keratin 19 (KRT19) is a Type-I keratin 
expressed in simple epithelia. Clinically, keratin 19 is used together with keratin 18 to 
distinguish between hepatocellular carcinoma and cholangiocellular carcinoma. Both 
keratins are expressed in bile ducts, but only keratin 18 is expressed in hepatocytes. This 
makes it an ideal marker for bile duct identification. Canalicular ATP-binding cassette (ABC) 
transporters are responsible for bile formation and secretion of bile acids, bilirubin and 
cholesterol. ABCB1 is responsible for the biliary excretion of xenobiotics across the 
canalicular membrane. There are some descriptions that indicate this is a hepatocyte 
expressed gene, however given the bile duct canaliculus represents the interface between 
the bile duct and the hepatocyte plate other studies have defined it as a biliary marker. I 
also selected Hnf1β as a candidate bile duct transcription factor since in development 
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Hnf1β knock-out mice fail to generate bile ducts and as such it, along with HNF6 are seen as 
archetypal biliary transcription factors.  
To determine the levels of parenchymal contamination I chose albumin and HNF4α, 
both of which are known to be restricted to hepatocytes. Hepatocytes manufacture 
albumin to maintain the oncotic pressure of plasma. Hence, albumin represents a marker 
present in hepatocytes and highly expressed in whole liver but absent in bile ducts. 
Hepatocyte nuclear factor 4α (Hnf4α) is a transcription factor in hepatocytes that controls 
expression of liver secreted glycoproteins; it is not expressed in bile ducts. It is necessary 
for hepatocyte development and differentiation and is largely seen as the archetypal 
hepatocyte transcription factor. 
Sox9 is also restricted to the adult biliary tree, so I chose to look at this following 
isolation. However, there are also reports that Sox9 is expressed in periportal hepatocytes.  
By carrying out RT-qPCR, I found that the level of transcript for markers of the bile 
ducts, Krt19 (p=<0.0001) (Fig.4.2A) and ABCB1 (p=0.0002) (Fig.4.2B) are significantly higher 
in the bile duct enriched fraction compared to total liver. Interestingly, Sox9 (p=0.0889) 
(Fig.4.2F) is also enriched, but not significantly, and Hnf1β (p=0.0068) (Fig.4.2D) is 
expressed in whole liver and reduced, by comparison in the ductal sample. This is curious, 
however could represent for Sox9 at least that there is a sufficient level of Sox9 in the 
parenchymal cells in the liver, therefore total levels in both hepatocyte and cholangiocyte 
populations is high. Our data on Hnf1β is more surprising given its role in development, 
however given that these livers are homeostatic and the bile ducts are not turning over 
particularly, it could be that Hnf1β is not being actively transcribed and therefore its 
abundance in the bile ducts is relatively low.  
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We also found that the hepatocyte markers, albumin (p=<0.0001) (Fig.4.2C) and 
Hnf4α (p=<0.0001) (Fig.4.2E) are significantly over expressed in the whole liver samples 
compared to the bile duct samples, in which there was almost no detectable expression of 
either hepatocyte transcript.  
From these data I can show that my duct enrichment protocol significantly 
improves the isolation of a population of ductal cells.  It is clear microscopically that this 
protocol does not produce immaculately clean ducts and that there are likely some 
hepatocytes remaining in these preparations which have not been digested away, however 
it is a balance between maintaining the duct tissue and this contamination. However, based 
on this RT-qPCR data this is a not an issue for using this protocol in future experiments 
however data generated from tissue which has been enriched for ducts should also be 
validated with IHC or RNA in-situ in tissue to confirm that expression is not due to 






  Figure 4.2 QPCR data showing relative expression of key markers of liver and bile duct 
in whole liver and enriched bile duct samples originating from the same liver, 
demonstrating enrichment of a biliary population of cells. A, Krt19 relative expression. 
B, ABCB1 relative expression. C, Albumin relative expression. D, Hnf1β relative 
expression. E, Hnf4α relative expression. Sox9 relative expression. Data is analysed 
using the Mann Whitney Test with a 95% confidence interval. p<0.05 was deemed to 
be statistically significant. n=10 biological replicates 
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4.3 Development a Cholangiocyte Organoid Protocol following enrichment of bile ducts 
The isolation of bile ducts from the liver is important for my descriptive work, 
however to determine functionally what the role of Vangl2 is in bile duct regeneration I 
decided to establish an in vitro culture of bile duct organoids in which we can modulate the 
expression of Vangl2.  
Following bile duct extraction and enrichment I re-suspended the isolated ducts in 
Matrigel to provide a three dimensional environment. Matrigel is a combination of 
laminins, collagen-IV, heparin sulphate proteoglycans and entactin. Rather than using this 
to form a 2-dimensional polymer base of the tissue culture plastic, I let the Matrigel 
partially polymerise before plating, as a result the bile ducts are cultured in a raised dome 
of Matrigel. Bile ducts were cultured with media containing a number of growth factors and 
small molecule inhibitors. These growth factors fall into distinct classes and are necessary 
for expansion:  
1. Mitogen growth factors, which activate MAPK signaling.  
2. Wnt pathway activators, which hyper activate Wnt signaling.  
3. TGFβ and ROCK inhibitors that inhibit EMT,  
4. Forskolin that potentiates cAMP production  
5. Vitamins and amino-acids 
The composition of the media can be found in materials and methods. After 24 
hours in culture we see the isolated bile ducts close off their open extremities to form 
capped-off tubules within the matrigel. Expansion of the bile ducts occurs over the 
following two days, and we see that there are cystic like structures which bud-off the sides 
and ends of the ducts (Fig.4.3 B,C). These are initially small, but undergo very rapid 
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expansion after 2 days. After three days the bile ducts are ready to be passaged. The duct 
like structures are still obvious at this point, however at 3 days they are covered in large, 
cystic organoids. During passage, organoids are removed from their matrix and are 
dissociated into fragments by manual disruption and re-embedded in Matrigel. Each 
fragment will generate a spherical organoid within 24 hours and over the following three 
days these organoids grow increase in size. After passaging/expanding the population twice 
more the organoids are significantly cleaner, with the absence of single cells that have 
carried over from the initial duct isolation. In the space of 7-10 days it is possible to 
generate a 24 well plate with sufficient organoids for experimentation, this is a significant 
improvement on previous assays where generation of organoids took a number of months. 
This method also has the benefit that we can isolate organoids form transgenic animal 







Figure 4.3 Progression of Organoid growth and development. A, Bile duct at day 0. B, Bile 
duct at day 1. C Bile duct at day 2. D Organoids at day 7 after first passage. Scale bar is 
400μm in A,B and D.  Scale bar is 1000μm in C. 
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4.4 Summary of Bile duct enrichment and Validation 
In this chapter, I have shown how I developed a methodology in the lab to isolate 
and culture bile duct organoids. The importance of enriching for our cell population of 
interest is central as it only makes up 20% of the adult liver and therefore the confounding 
background in this type of analysis would be difficult to overcome, particularly as I am 
investigating changes in lowly expressed proteins. I have refined a duct extraction protocol 
to not only be faster and more efficient but that can deliver ducts that are capable of going 
on to generate organoids at a faster rate. I successfully validated the duct enrichment by 
showing a significant difference in key markers of both bile duct and whole liver. In 
particular, the use of Krt19 and ABCB1 as bile duct markers and albumin and HNF4α as a 
measure of whole liver or hepatocyte population clearly supports this. Finally, I successfully 
established a bile duct organoid protocol that is efficient and can be consistently carried 
out. These organoids will be used in my project and more generally by the lab to look at the 
functional role of signals in bile duct regeneration and cancer and therefore constitute an 




Chapter 5 – Characterisation of Vangl2 and Non-Canonical 
Wnt Pathway Components in the Regenerating Bile Duct 
Whilst the role of Vangl2 and non-canonical Wnt signaling has been functionally 
determined during embryogenesis using a combination of genetics from patients with 
neural tube closure defects and animal models, the function of Vangl2 and non-canonical 
Wnt signaling in adult tissues remains largely undetermined with work largely being limited 
to muscle, epidermis and cancers.  
 
5.1 DDC Model 
The 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) model was selected as a non-
oncogenic model of primary sclerosing cholangitis. The DDC model is a consistently 
applicable and recognised method of drug-induced cholestatic liver injury in the mouse. 
Mice tolerated the diet for up to 14 days, with additional experimental time points at days 
5, 10 and 14, at which point they were sacrificed. 
 
5.2 QPCR for Non-Canonical Wnt Pathway Components 
Using tissue challenged by the DDC diet at 5 days, 10 days and 14 days and 
compared against uninjured tissue I investigated known receptors and their cited 
corresponding ligands (Niehrs, 2012). 
During the experimental period, I found a significant upregulation Vangl2 (Fig.5.1A) 
at all three time points when compared to the uninjured day 0 tissue (Vangl2, P=0.0006). 
There was no significant change found in Vangl1 expression (Fig.5.1B) (Vangl1, P=0.1306). 
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Of particular interest in this data is the remarkable upregulation at 5 days of DDC injury 
where Vangl2 is transcriptionally expressed at a mean of ~15-fold increase and Vangl1 is 
over 5 fold increased. The transcriptional upregulation also takes places at 10 days and 14 
days but is most strongly increased at 5 days. 
Ror2, a commonly associated Vangl2 and non-canonical Wnt co-receptor was not 
found the change during the injury period (p=0.595) (Fig.5.1C). 
I examined Wnt4 (Fig.5.1E), Wnt5a (Fig.5.1D) and Wnt11 (Fig.5.1F) as archetypal 
non-canonical pathway markers. Wnt11 showed evidence of change during the DDC injury 
progression (p=0.0231) (Fig.5.1F) by overall analysis with its greatest relative fold change at 
day 14. However, there was no change at day 5 or 10 and so it was not initially considered 
as a candidate ligand. Wnt4 showed a significant increase at 5 days (p=0.0107) (Fig.5.1E) 
but a drop in expression at 10 days and 14 days when compared against uninjured tissue. 
We had considered that Wnt4 could be an interesting candidate given it has previously 
been described as antagonistic to the canonical Wnt signaling pathway (Bernard P et al 
2009), and our lab has previously shown that the canonical signal is not activated during 
bile duct regeneration (Boulter et al 2013). In fact, it is suggested that the non-canonical 
Wnt pathway is actively inhibited by activated components of the non-canonical pathway 
featured in this case. Wnt5a mRNA expression is significantly upregulated at all time points 
(p=0.008) (Fig.5.1D), once again, as previously mentioned when referring to pathway 





Figure 5.1 qPCR data showing fold change of candidate pathway ligand, receptor and 
co-receptors transcription. A, Vangl2 mRNA fold change. B, Vangl1 mRNA fold change. 
C, Ror2 mRNA fold change. D, Wnt5a mRNA fold change. E, Wnt4 mRNA fold change. 
F, Wnt11 mRNA fold change. G, Combined mRNA fold change for Wnt4a, Wnt5a and 
Wnt11. Data is analysed using the Kruskal-Wallis Test with a 95% confidence interval. 




Frizzled (Fzd) is a G protein-coupled receptor that acts as the Wnt receptor in Wnt signaling. 
There are 10 known Frizzled receptors. The cysteine rich domain of the receptor interacts 
with Wnts but is not unique to Fzds as it also exists on other known receptors such as Ror2.  
The interactions of Wnt ligands with corresponding Fzd receptors is complex but 
we can narrow down potential receptors that may be being expressed in this case.  I 
assayed for Fzd receptors which are known to function in the non-canonical pathway; Fzd3, 
Fzd6 and Fzd8 as well as candidate Fzds which are known to function in the canonical 
pathway. Wnts reported to activate Fzd1 include Wnt1, Wnt8, Wnt3a, Wnt3, and 
Wnt2. Wnt5a apparently interacts with Fzd1 but does not signal. The only reported Wnt to 
interact with Fzd2 is Wnt5a.Wnt1 and Wnt8 are reported to bind to Fzd3. Wnts believed to 
bind to Fzd4 include Wnt1 Wnt8, and possibly, Wnt5a.Wnts reported to bind to Fzd7 
include Wnt5a, Wnt8, and Wnt11. Wnt8 is believed to be a ligand for Fzd8. 
 Conclusive data showed significant upregulation in transcription of Fzd3 
(P=0.006) (Fig.5.2C), Fzd4 (p=0.0064) (Fig.5.2D) and Fzd8 (p=0.008) (Fig.5.2G). As 
with the Wnt ligands I found significant upregulation at all time points but 
particularly at day 5 during injury, Fzd3 in particular demonstrated a mean 15-
fold change in mRNA transcription (Fig.5.2C). 
However, as in the case of Ror2, Fzd is not always the Wnt receptor 
activating the pathway. It would be encompassing to investigate other receptor 
tyrosine-kinases that reportedly operate in a similar fashion to Ror2, particularly 
given my data for Ptk7 expression (Fig.5.3E and Fig.5.5). Other RTK’s such as Ror1 






Figure 5.2 qPCR data showing fold change of candidate pathway receptor 
transcription. A, Fzd1 mRNA fold change. B, Fzd2 mRNA fold change. C, Fzd3 mRNA 
fold change. D, Fzd4 mRNA fold change. E, Fzd6 mRNA fold change. F, Fzd7 mRNA fold 
change. G, Fzd8 mRNA fold change. Data is analysed using the Kruskal-Wallis Test with 




Disheveled (Dvl) proteins are a family of proteins involved in the canonical and non-
canonical Wnt signaling pathways. Historically, Dvl’s roles are closely linked to that of the 
canonical Wnt pathways but also plays an important role in cellular differentiation and cell 
polarity. In the canonical Wnt signaling pathway, Dvl is phosphorylated where it 
polymerises and sequesters Axin at the cell membrane by the activation of Fzd by Wnt 
rendering B-catenin free of the destruction complex and activating the canonical Wnt 
signaling pathway. There are three evolutionary conserved murine forms Dvl1, Dvl2 and 
Dvl3. 
I examined at the transcription of Disheveled to investigated downstream 
activation of the Wnt pathway. I found no change in Dvl2 during bile duct injury (p=0.6489) 
(Fig.5.3B). However, both Dvl1 and Dvl3 were upregulated across the injury time course 
(Dvl1, P=0.0383 (Fig.5.3A). Dvl3, p=0.011 (Fig.5.3C)). Once again, significant upregulation of 
mRNA transcription was found at all time points during injury but particularly high 
transcriptional fold change was found to be occurring at day 5, a feature noted in Vangl2 
expression and some Wnt ligands. 
To investigate further possibilities of a co-receptor being present I investigated Ryk 
and Ptk7 expression. Ryk is a known non-canonical Wnt pathway co-receptor that binds 
with Wnt and directly activates Dvl. It was found to be significantly upregulated at all time 
points during injury (p=0.021) (Fig.5.3D) but particularly at day 5 exhibiting a 5-fold 
increase. Ptk7 is a transmembrane pseudokinase known for its role as a regulator of the 
Wnt mediated planar cell polarity pathway. I found it to be significantly upregulated during 
the injury time course (p=0.0192) (Fig.5.3E) with an increase in relative transcription over 





Figure 5.3 qPCR data showing fold change of Disheveled and Ryk co-receptor. A, 
Dvl1 mRNA fold change. B, Dvl2 mRNA fold change. C, Dvl3 mRNA fold change. D, 
Ryk mRNA fold change. E, Ptk7 Relative Expression. Data is analysed using the 
Kruskal-Wallis Test with a 95% confidence interval. p<0.05 was deemed to be 




5.3 In Situ Hybridisation for Vangl1 and Vangl2 
With data strongly supporting the hypothesis that Vangl2 and the non-canonical 
Wnt pathway are involved in the regenerating bile duct I wanted to clarify the location of 
the upregulated mRNA transcription. I did this by in situ hybridisation, probing for Vangl2 
mRNA in regenerating tissue from the DDC injury model. I found positive signals for the 
mRNA in the bile duct epithelium with what looks to be an increased expression of signal as 
the DDC injury model progressed (Fig.5.4). This is subjective though, this data would need 








Figure 5.4 Upper panels In Situ Hybridisation by RNAScope showing Vangl2 mRNA 
expression, highlighted by arrows, with spatial localisation of the Bile Duct (b.d.) and Portal 
vein (p.v.) during DDC injury at days 0, 5 and 14. Immunohistochemistry demonstrating 




5.4 Vangl2 and Ptk7 protein expression during injury 
Dual stained immunofluorescent staining of Vangl2 and PTK7 reveals potential co-
localisation of the two receptors, proposing a role for PTK7 interacting with Vangl2 in 
receiving a Wnt ligand during regeneration of the bile duct (Fig.5.5). 
I also examined at Vangl2 expression by immunohistochemistry over the injury 
process finding increased expression as injury progressed. Unlike the qPCR data I did not 
see such high expression at day 5 that then receded, instead I saw a steady increase in 
expression as the time course progressed (Fig.5.5). This may be because the pathway is 
activated in response to injury at which point it drives Vangl2 expression to ensure a 
complete response against the expected ligand. Once Vangl2 is translated from mRNA it is 
expressed on the cell surface but we have no data on the half-life of the receptor 
expression, perhaps it is expressed there for some time relative to the injury progression? 
The transcriptional response may also be appropriate for the ligand expression and 
regenerative purpose. Once the initial response resulting in high Vangl2 expression is 
achieved the system may only require minimal expression, in comparison to early 
expression, to maintain the desired response. Vangl2 expression was localised to the 
vicinity surrounding the bile duct. 
Ptk7 showed a similar pattern of expression to that of Vangl2 with increased 
expression as injury progressed and localisation to the bile duct (Fig.5.5). Of interest, PTK7 
is also expressed in the fibroblasts surrounding the Vangl2 positive epithelium, prior to the 
epithelium expressing PTK7. This suggests that the fibroblasts surrounding the duct may 
utilise PTK7 independent of Vangl2 to regulate their function, however further experiments 
would be needed to test this hypothesis.  
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I did immunofluorescence to look for instances of co-localisation of Vangl2 and 
PTK7. Under confocal microscopy the expression of both proteins looks consistent with 
what we would expect should they be expressed in the same regions but of course there 
are still limitations to truly explore this hypothesis. Ideally, to investigate this would require 
at least two techniques. I would utilise a co-immunoprecipitation approach to confirm 
molecular interaction with both proteins. This would not demonstrate localisation but 
would confirm the possibility of both receptors existing within a bound state. I could then 
build on this using Fluorescence Resonant Energy Transfer (FRET). In a FRET experiment the 
potential binding partners are labelled with spectrally distinct fluorophores in such a way 
that the emission spectrum of the donor molecule overlaps the excitation spectrum of the 
acceptor molecule. If both interaction partners are in close contact at a distance of only a 
few nanometers, the excited donor can transfer its energy to the acceptor. In turn, the 
acceptor emits a fluorescence photon and the fluorescence lifetime of the donor molecule 
decreases. This demonstrates a relative co-localisation within a given distance. The 































Figure 5.5 Immunofluorescence of dual stained tissue during DDC injury at day 0, 5 and 14 
showing Vangl2 in green, Ptk7 in red and nuclear DNA in blue. Yellow signal demonstrates co-
localisation of green and yellow signals of Vangl2 and Ptk7. These instances are highlighted by 
arrows. Bile Ducts (b.d.) are indicated for reference. 
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5.5 Identification of Vangl2 in Human bile ducts  
Previous work from our group has shown that in cholangiocarcinoma, a cancer of the 
intrahepatic bile ducts, Vangl2 is over expressed at the mRNA level in cancer compared to 
uninvolved human tissue. To determine whether Vangl2 is expressed in normal and 
diseased human liver, we identified material from patients who had a diagnosis of PSC 
versus patients who had a normal liver pathology. 
Patient matched samples of PSC and healthy tissue from the same patient were 
investigated for evidence of Vangl2 transcriptional upregulation and protein expression. I 
found, using qRT-PCR, that there was a significant up regulation of Vangl2 mRNA transcript 
(P=0.023) (Fig.5.6B) when compared to non-disease tissue. However, the same was not the 
case when Vangl1 expression was investigated, no significant difference was found 
between PSC and normal tissue (p=0.143) (Fig.5.6A). Whilst qRT-PCR is useful to determine 
whether Vangl2 is expressed, it does not provide any information about where transcripts 
or proteins are expressed within the tissue. To better understand this, I used 
immunohistochemical staining using anti-Vangl1 and anti-Vangl2 antibodies that I have 
optimised during my MScR. I found that for both Vangl1 and Vangl2 proteins are localised 
to the biliary epithelium in both normal and PSC tissue (Fig.5.6C). Whilst 
immunohistochemistry is useful for identification of protein localisation it does not tell us 
about the levels of Vangl2 protein in the bile ducts. To do this I would need to isolate bile 
ducts from both normal and PSC tissue and use a quantitative method to determine the 
levels of Vangl1 and Vangl2 protein in these samples using Western blotting. Given these 
samples are derived from the NHS ACCORD tissue bank, and are formalin fixed this was not 
possible from the samples we had available.  
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Vangl2 is a transmembrane protein, which is known to interact with a number of 
Wnt ligands via other co-receptors. We had determined in our mouse model of PSC, the 
DDC diet, that Wnt4 and Wnt5a were significantly over expressed compared to baseline, 
and could show that Wnt5a was expressed in CD68 positive inflammatory cells using 
immunohistochemistry. To confirm this in the context of human disease, I investigated 
whether the ligand for Vangl2 was indeed, Wnt5a, and found a significant up regulation of 
its transcript (p=0.024) (Fig.5.6D) and I could also find small cells which expressed Wnt5a 
protein by immunohistochemical staining (Fig.5.6E). These cells were localised in the 
vicinity of the bile duct, however were not bile duct epithelium and are likely to be 
inflammatory cells. To confirm this, I would need to stain PSC and normal tissue with both 






Figure 5.6 Identification of Vangl2 in hCCA. A Vangl1 relative expression. B Vangl2 relative 
expression. C Immunohistochemistry showing Vangl1 and Vangl2 protein expression with 
Bile Duct (b.d.) and Portal Vein (p.v.) highlighted. D Wnt5a relative expression. E 
Immunohistochemistry showing Wnt5a protein expression with Bile Duct (b.d.) 
highlighted. For RT-qPCR the data is analysed using the Mann Whitney Test with a 95% 
confidence interval. p<0.05 was deemed to be statistically significant. n=17 
63 
 
5.6 Summary of qPCR and immunohistochemistry for non-canonical Wnt Pathway 
Components during bile duct injury 
 Here I show strong evidence for the transcriptional upregulation of key 
components of the non-canonical Wnt pathway during bile duct injury and validate some of 
this data by In Situ hybridisation and immunohistochemistry to show the presence of the 
protein. 
 I initially looked for evidence of an archetypal receptor ligand complex. I found 
strong upregulation of Vangl2, Wnt5a, Wnt4, Fzd3, Fzd4 and Fzd8. Vangl2 mRNA was 
localised to the bile duct epithelia by RNAScope In Situ hybridisation and 
immunohistochemistry. 
 I highlighted the activation of a membrane bound Wnt pathway receptor by looking 
for evidence of Dvl transcription, finding Dvl1 and Dvl3 both upregulated. 
 I found evidence suggesting a role for PTK7 as a co-receptor by showing increased 
transcriptional expression as well as immunohistochemistry. The immunohistochemistry 
hinted at co-localisation with Vangl2 but this will need further work to elucidate. 
 Finally, I used human samples of Primary Sclerosing Cholangitis to show potential 





Chapter 6 - Modulation of Vangl2 using the Looptail mutation 
6.1 Characterisation of the Looptail mutation. 
Looptail mice feature a missense point mutation converting a serine to and 
argenine (S464N) (Fig.6.1A). Vangl2 is transcribed correctly and translocated to the nucleus 
but fails to function as a transmembrane receptor.   The mutation operates in a semi-
dominant fashion over the wild-type locus; heterozygotes display the looped-tail 
appearance while homozygotes show the neural tube defect craniorachishisis in which it 
fails to close during development. Therefore all experiments are conducted with Vangl2+/+ 
and Vangl2Lp/+. The obvious looped or kinked tail is a clear visual marker of phenotype; the 
mutation also contributes to perturbed cilia function in the inner ear canal. This is 
demonstrated by poor balance and coordination and a characteristic head tremor.   
To confirm the transcriptional activity of Vangl1 and Vangl2 I conducted qPCR. The 
S464N mutation causes no issue in transcription of mRNA or the translation of protein. The 
Looptail mutation disrupts delivery of Vangl1 and Vangl2 proteins to the cell surface as a 
result of oligomer formation between Vangl1 and Vangl2S464N, or Vangl2 and Vangl2S464N, 
coupled to the intracellular retention of Vangl2S464N. As a result, Vangl1 protein is missing 
from the apical cell surface of vestibular hair cells in Looptail mutants, but is retained at the 
apical cell surface of hair cells in vangl2 knockouts. As expected I saw no change in mRNA 
relative expression (Vangl1, p=0.7247) (Fig.6.1B). Vangl2, p=0.7424) (Fig.6.1C). A number of 
descriptions have also indicated that Vangl2 can traffic normally to the plasma membrane 
in certain cells where it functions as a functionally dead receptor. 
I investigated the protein expression of Vangl2 during injury using our DDC model 
with time points at 5 and 14 days. No difference was noted in expression between the 
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Vangl2+/+ and Vangl2Lp/+ phenotypes (Fig.6.2). This is unsurprising as Vangl2 is non-
functional as a receptor due to the point mutation but still retains the epitope recognised 
by the Vangl2 antibody used. The protein is translated as normal and a non-functional form 
expressed at the cell surface. 
 
  
Figure 6.1 A, a schematic showing the C-terminus point mutation featured in the Looptail 
mouse. B, Vangl1 relative expression in the Looptail and wildtype mouse. C, Vangl2 
relative expression in the Looptail and wildtype mouse. qPCR data is analysed using the 
Mann Whitney Test with a 95% confidence interval. p<0.05 was deemed to be 






Figure 6.2 Immunohistochemistry demonstrating Vangl2 protein expression in the 
Wildtype and Looptail mouse at days 0, 5 and 14 during biliary injury by DDC. Bile Ducts 
(b.d.) and Portal veins (p.v.) are highlighted for reference. 
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6.2 Characterisation of DDC injury in Vangl2Lp/+ mice 
I used a Picro-Sirius Red histology stain as an indicator of fibrosis and measured this 
at day 0 day 5 and day 14 (Fig.6.3E). Sirius Red stains all collagen fibers. I used ImageJ to 
quantify the area of tissue with positive staining and compared this against to the total area 
of tissue. I found in both genotypes, Vangl2+/+ and Vangl2Lp/+ an increase in fibrosis. 
However, at each time point during injury the Looptail mouse Vangl2Lp/+ was found to have 
significantly less fibrosis than its comparable littermate wildtype (Day 5, p=0.034. Day 14 
p=0.002) (Fig.6.3A). I investigated whether this was reduced expression in a specific isoform 
of collagen within the fibrilar tissue (Fig.6.3F). I found no change in Collagen-III (data not 
shown) but Collagen-I yielded significant changes. As seen in the analysis of overall fibrosis 
both genotypes, Vangl2+/+ and Vangl2Lp/+, showed an increase in Collagen-I during injury. 
However, at each time point the Looptail mouse Vangl2Lp/+ was found to have significantly 
less fibrosis than its comparable littermate wildtype (Day 5, p=0.030. Day 14 p=0.002) 
(Fig.6.3B). 
I investigated the cell populations that contribute to the fibrogenic response during 
injury to ascertain whether the populations themselves were increasing resulting in an 
increase in fibrosis. While the cellular populations do increase during injury ductular 
fibroblasts (αSMA+) (Fig.6.3C and Fig.6.3G) and stellate cells (Desmin+) (Fig.6.3D and 
Fig.6.3H) remain unchanged throughout the time course when comparing Vangl2+/+ and 
Vangl2Lp/+. A possible hypothesis is that rather than altering the number of fibrogenic cells 
within the liver, the fibrogenic capacity of these cells is being regulated by Vangl2. 
Alternatively, Vangl2 is playing a role involved in trafficking MMP14 to the cells surface as 
part of the fibrogenic response in extra cellular matrix deposition (B. B. Williams et al., 





Figure 6.3 Analysis of aspects of fibrosis and contributing cell populations in Looptail mice. 
A, Quantification of positive PSR staining in Looptail and Wildtype mice during DDC injury. 
B, Quantification of positive Collagen-I staining in Looptail and Wildtype mice during DDC 
injury. C, Quantification of positive α-SMA staining in Looptail and Wildtype mice during 
DDC injury. D, Quantification of positive Desmin staining in Looptail and Wildtype mice 
during DDC injury. Data is analysed using the Mann Whitney Test with a 95% confidence 
interval. p<0.05 was deemed to be statistically significant. n=5. E, Representative image 
showing PSR staining and threshold mask of day14 Looptail liver. F, Representative image 
showing Collagen-1 staining and threshold mask of day14 Looptail liver. G, Representative 
image showing α-SMA staining and threshold mask of day14 Looptail liver. H, 
Representative image showing Desmin staining and threshold mask of day14 Looptail liver. 
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6.3 Summary of Vangl2 modulation 
 Here I used the Vangl2 heterozygous mutant mouse, referred to as Looptail due to 
its phenotypic tail which varies from a mild kink to curled, to investigate the cellular 
response to injury when functional Vangl2 expression is significantly reduced. 
I, initially, characterised the Vangl2 present showing that despite the serine to 
argenine (S464N) mutation Vangl2 was still transcriptionally expressed as normal and that 
by immunohistochemistry the protein was still trafficked to the cell membrane and 
presented. 
I then investigated the fibrotic and cellular response to injury using our previously 
DDC model of bile duct injury. I found significantly less fibrotic tissue formed at all injury 
time points and that this fibrotic tissue was comprised of less Collagen-I when compared to 
the Vangl2+/+ littermates. This brings up a number of avenues which we can explore to 
investigate the potential link between non-canonical Wnt mediated signaling, regulated by 
Vangl2, in the liver during bile duct injury and the livers fibrotic response to ductal 
challenge. I touched on it briefly to look at the cellular populations that would be 
contributing to fibrogenesis. A decrease in cell population may correspond to the decreased 
fibrosis found. However, this was hypothesis was not supported and so at the moment I 
must assume that the fibrogenic capacity of these cells has somehow been influenced by 
the reduction in functional Vangl2. 
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Chapter 7 - Discussion 
Chronic biliary disease is caused by a number of cholangiopathies including primary 
biliary sclerosis, primary biliary cholangitis and a number of autoimmune pathologies. 
Together, these account for a significant, and increasing number of liver disease diagnoses 
each year. Whilst often considered as end-stage disease pathology these bile duct diseases 
arise on the background of long-term iterative damage and regeneration, resulting in cycles 
of inflammation and fibrosis.  
In the earliest phases of these diseases, pathology is not established and the 
formation of a local fibrotic microenvironment around damaged ducts is an attempt to 
regenerate the diseased epithelium whilst concurrently partitioning off this section of injury 
from the remainder of the organ to prevent the dissemination of disease throughout the 
tissue (Ramachandran & Iredale, 2012). Here, prior to established disease, this fibrotic 
microenvironment is known as the regenerative niche and represents a transient and highly 
specialised microenvironment through which the bile duct is able to regenerate following 
injury.  
Work from the Boulter lab and others have previously demonstrated that this 
regenerative microenvironment is comprised of a complex mixture of fibrogenic αSMA 
positive fibroblasts, macrophages, neutrophils and T-cells (Boulter et al., 2012; Greenbaum 
& Wells, 2011; Viebahn et al., 2010). This complex microenvironment results in the 
deposition of extra-cellular matrix (ECM), which consists of collagen-1 and collagen-3, but 
also contains large amounts of laminin, which is known to have a functional role on the 
biology of the regenerating bile duct.  The cellular components of this regenerative niche 
are also critical for correct biliary specification and the correct patterning of the 
regenerating ducts.  
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One major question that remains regarding ductular regeneration is how does the 
regenerative microenvironment get recruited and, importantly, how does the damaged 
epithelium communicate to the surrounding niche to affects its biology, ensuring that scar 
formation is linear to the level of injury, for example? 
The Boulter lab is interested in the role of Wnt signaling in liver regeneration and 
cancer and had previously shown that Vangl2, a component of the non-canonical Wnt 
receptor complex was over expressed in bile duct cancer. Given that Vangl2 has been 
previously implicated in the turnover of ECM in the developing embryo (B Blairanne 
Williams, Mundell, Dunlap, & Jessen, 2012) we sought to investigate, in adult bile duct 
disease, whether Vangl2 was involved in ECM deposition or turnover.  
Here, we are able to show that the non-canonical Wnt receptor Vangl2 is 
upregulated in bile duct disease compared to healthy liver. Our initial investigations on 
whole tissue were positive and led us to define the other non-canonical Wnt co-receptors 
that are likely to be expressed in bile ducts. Enrichment of the bile ducts is crucial when 
investigating the relatively small population of cells that comprises these structures and in 
particular when investigating low levels of transcript as is the case in these signaling 
pathways. In order to address this limitation of cellular dilution by the parenchyma, I 
established a protocol through which I could isolate the bile ducts from whole liver, thereby 
enriching the transcriptional abundance of our targets compared to whole liver.  My 
approach to enrich for the population of cells of interest was wholly successful as 
demonstrated by the qPCR validation data I obtained identifying recognised ductal markers, 
K19 and ABCB1 in the suspected enriched fraction. Moreover, we could then test these 
enriched bile duct samples to confirm whether the non-canonical Wnt receptor Vangl2 and 
PTK were expressed here, which they were. This is the first description in the adult of 
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Vangl2 and PTK7 being expressed in the adult bile duct, and is in line with previous 
evidence from the developing liver in zebrafish that Vangl2 might be important for the 
formation and indeed regeneration of the bile duct (Cui, Capecci, & Matthews, 2011b; 
Wilkins & Pack, 2013).    
As part of this identification and classification I established a protocol to culture bile 
ducts in Matrigel and expand these as organoids. This protocol is similar to the protocol 
established by Huch et al (Huch & Koo, 2015). However, through my protocol we can 
rapidly establish very large numbers of organoids. I had intended to use these organoids to 
more thoroughly define the sub-cellular localisation of Vangl2 at a single cell level, and this 
should be work done in the future. The establishment of a biliary organoid protocol will 
prove to be of great use in the future, particularly as we will be able to modulate the non-
canonical signaling pathway through genetic alteration of Vangl2 or ligands such as Wnt5a. 
It will also provide me with a 3-dimensional model of bile ducts, facilitating wide scale 
screens and analysis in future projects.   
The non-canonical Wnt receptor Vangl2 does not operate independently and I 
therefore undertook a thorough characterisation of pathway components which, in other 
systems, have been shown to interact with Vangl2. Using qPCR, I showed that during injury 
we have a significant upregulation of non-canonical Wnt pathway receptors and ligands. 
The non-canonical ligands, Wnt4 and Wnt5a showed significant upregulation. Furthermore, 
GPRCs; Fzd3, Fzd4 and Fzd8 also showed significant transcriptional upregulation during 
injury progression, suggesting that these receptors could be a part of this receptor complex 
or could be involved in other signaling processes, such as the Wnt dependant 
calcium/calmodulin signalling pathway. Despite the transcriptional evidence for Fzd being 
present I could not achieve conclusive evidence by also demonstrating its presence by 
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immunohistochemistry or Western blot, which would represent further studies. It would 
also be important to show that these Fzd receptors physically interact with Vangl2 following 
stimulation with non-canonical Wnt ligands. To further elucidate the nature of the activated 
pathway it would be prudent to investigate downstream components that became 
phosphorylated or activated. I would initially continue exploring the archetypal non-
canonical components such as DAAM1, RHOA and ROCK. It would then be rational to 
evaluate whether G-Actin is being converted to F-Actin following upstream changes.  If we 
were to see cytoskeletal changes taking place, this could represent cell shape changes 
which could influence the local environment. Alternatively, RAC1 and JNK upregulation and 
activation might lead to cJUN/cFOS activation and changes in transcriptional activation of 
target genes, which are known to regulate inflammatory cytokines (Chopra, Kumar, 
Rangarajan, & Kondaiah, 2015; Pashirzad et al., 2016).  
To develop this further, it would be possible to perform RNAseq using the Looptail 
mouse following the DDC injury model. This would give broad scope insight into pathway 
activations, from this we would be able to use Gene Ontology (GO) term analysis which 
would allow us to determine which downstream pathways are changed by the Looptail 
mutation. Given my data showing that the Looptail mutant mice have reduced fibrosis 
compared to their non-mutant littermates, we have concluded that Vangl2 is involved in 
the fibrotic response during injury. However, at the moment we have little information of 
how this is functioning. Changes in the amount of ECM does not necessarily mean there is a 
change in the composition of the ECM. By isolating the ECM fraction from Looptail and 
control mice we would be able to use the tissue to analyse ECM by mass spectrometry, this 
is something that could lead to a number of interesting leads in future studies. This would 
clearly allow us to understand as to whether certain components of the ECM are expressed 
differently during bile duct injury when Vangl2 is mutated. 
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The Looptail mouse, is a commonly employed tool used to investigate the function 
of Vangl2 in adult tissues. However, it is limited in some regard as the mutation can only be 
maintained in the adult as a heterozygote and whilst there is a clear phenotype it is 
impossible to know whether this represents haploinsufficiency and whether this phenotype 
can be enhanced by homozygous loss. Moreover, Vangl2 function is affected wherever 
Vangl2 is expressed and does not target the biliary niche I am looking specifically at in this 
project. As a result, we cannot say, absolutely, that the phenotype in the Looptail mouse 
we have described is due to loss of Vangl2 function in the bile ducts, although this is likely it 
could be due to loss of function in other cells which affect fibrosis or due to systemic 
changes in the Looptail mutant mouse. A more refined approach would be to use a Cre 
mediated knockout of Vangl2. To do this I would use Cre recombinase expressed from 
biliary specific promoter, such as Kertain19, Sox9 or Hnf1β, all of which have been 
previously described. These mice would then be crossed with a Vangl2-flox line. A suitable 
existing option would be the Vangl2flox mouse used previously by Henderson et al to 
demonstrate adult corneal epithelial cell alignment and migration and patternation of the 
second-heart field (Findlay et al., 2016). I would then conduct a repeat of the Looptail 
experiments using this mouse line specifically lacking biliary Vangl2. I would expect the two 
genotypes, Vangl2Lp/+ and Vangl2flox to phenocopy one another, however mice with the 
Vangl2 homozygous flox allele could have a more significant phenotype. Given that the 
Looptail mutation is dominant over the wild-type copy in the Looptail mouse, the changes 
we see may be very similar to the constitutive mutation.  
Whilst there have been a large number of small molecules which have been trialed 
in both rodent models and human diseases targeted against the canonical Wnt signaling 
pathway, there are relatively few therapeutics which can be used to inhibit the non-
canonical Wnt signaling pathway. One way of antagonising the non-canonical Wnt pathway 
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would be to affect the expression or production of Wnt ligand or to block the activation of 
the non-canonical Wnt receptors. The use of LGK974 has been recently described as a small 
molecule inhibitor of PORCN (Porcupine) to target Wnt-driven cancers (Liu et al., 2013). 
Porcupine regulates Wnt secretion via the endoplasmic reticulum by mediating the 
palmitolyation of the Wnt ligands. Inhibition of porcupine prevents the secretion of Wnt 
from its source cell and results in Wnt ligand accumulating in these cells. I would treat mice 
with biliary injury with LGK974 to inhibit Wnt ligand production and evaluate whether this 
is sufficient to reduce the deposition of collagen in vivo.  
A further strategy to reduce the amount of Wnt ligand produced in this system 
would be to inhibit the cell of origin. Macrophage derived Wnt in the liver has been 
highlighted as playing a role in specifying hepatic progenitor cells and also in liver cancer. 
Macrophages have been implicated elsewhere as being the source of secreted Wnts 
(Boulter et al., 2012). Their mobility makes them well suited to translocating to injury sites 
to deliver highly localised ligands in a damage dependent context. Investigating 
macrophages as a Wnt source and modulator of fibrosis would be straightforward. Initially, 
macrophage population would be identified with a known marker like F4/80 or CD68. This 
would allow for identification of macrophage localisation, which under DDC would be 
surrounding the bile ducts, as previously described. This could be combined with 
immunohistochemistry for Wnt4 and Wnt5a, which I have shown, are up regulated in the 
DDC model. Assuming a correlation in macrophage and Wnt localisation the following step 
would be macrophage ablation, to remove the suspected source of Wnt during biliary 
disease. This could be done using compounds such as liposomal clodronate, which would 
ablate phagocytic macrophages or through inhibiting the CSF1 receptor. 
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The non-canonical Wnt signaling pathway is poorly described and there is a lack of 
rigorous functional description of non-canonical Wnt pathway and its role in adult liver 
disease, compared with its canonical counterpart. This means that there is plenty of scope 
for novel descriptions and functional characterisation of non-canonical pathway activation 
and its role in disease. Whilst originally described as a mechanism to ensure polarity of 
epithelial sheets (Vladar, Antic, & Axelrod, 2009), non-canonical Wnt signaling is now 
largely accepted to have a much more diverse role, particularly in the adult where 
confluent morphogenic movements are not required (Freese, Pino, & Pleasure, 2010; 
Fuerer, Nusse, & Ten Berge, 2008; Roel Nusse & Nusse, 2005).  
In this MScR, I have shown that there are non-canonical Wnt pathway components 
expressed in a model of bile duct disease and regeneration. I propose a novel role for 
Vangl2 and the non-canonical Wnt mediated pathway. While Vangl2 has been previously 
described as an effective co-receptor for Frizzled in the case of this body of work I would 
suggest it is acting either independently or as a co-receptor in companion with Ptk7. 
Through this complex, the non-canonical Wnt signaling pathway is receiving ligand 
stimulation, potentially Wnt4 or Wnt5a and activating downstream signaling in a hitherto 
undescribed manner.  
Given the reduction I observe in fibrosis in the Vangl2Lp/+ mutant mouse subjected 
to the DDC injury model, this provides a strong insight into the bile-duct specific activation 
of the non-canonical Wnt pathway via Vangl2. Recent work by Williams et al demonstrated  
a role for Vangl2 in trafficking MMP14 to facilitate cell polarity and migration (B. B. Williams 
et al., 2012). Subsequently, the same group described a role for Vangl2 dependent sorting 
in the late endosome, which regulated the presentation of MMP14 at the cell surface. 
Mutations in Vangl2 resulted in a failure to endocytose MMP14 and therefore resulted in a 
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higher concentration of MMP activity at the cell surface. This MMP is also known to 
activate a number of cytokines, soluble MMPs and also can turn over collagen, indicating 
that in our model system, loss of Vangl2 could in fact regulate the local microenvironment 
through deregulation of bile duct MMP14 activity. (B Blairanne Williams et al., 2012).  
Finally, I have used fibrosis as a readout of change when Vangl2 is altered in the 
mutant Vangl2 model. However, it would be interesting to combine this data with 
physiological sampling such as liver function, which would represent the functional output 
of the liver which may be altered following deregulation of Vangl2.  
Ultimately, I have shown, for the first time that the non-canonical Wnt signaling 
pathway is expressed in bile duct regeneration and that it represents an attractive 
therapeutic target to modulate the fibrotic response in the adult liver. There remains a 
great deal of work to do to properly understand the mechanisms behind this pathway in 
this disease process, however I have functionally shown that this pathway is important by 
using a mutant allele of Vangl2 and have surprising demonstrated that this is not due to 
changes in the bile duct proliferation or patterning, but functions potentially in a cell non-
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